Non-Invasive Gene Expression Testing to Rule Out Melanoma

Area of Science:

• Dermatology
• Molecular Diagnostics
• Oncology

Background:

• Melanoma diagnosis relies on visual inspection and histopathology, which has limitations.
• Current diagnostic methods have a low negative predictive value (NPV), leading to unnecessary biopsies.
• Atypical pigmented lesions pose a diagnostic challenge, often requiring invasive procedures.

Purpose of the Study:

• To evaluate the utility of the Pigmented Lesion Assay (PLA) in ruling out melanoma.
• To assess the impact of PLA on reducing surgical biopsies for skin lesions.
• To improve the accuracy and efficiency of melanoma diagnosis.

Main Methods:

• The Pigmented Lesion Assay (PLA) analyzes gene expression (PRAME, LINC00518) from skin samples collected non-invasively.
• The assay provides a binary result (positive/negative) based on gene expression levels.
• Results are compared to traditional histopathology for diagnostic accuracy.

Main Results:

• PLA demonstrates a very high negative predictive value (>99%), significantly outperforming traditional methods.
• The assay shows high specificity (69-91%), reducing false positives.
• Implementation of PLA reduced the number needed to biopsy for melanoma from 20-39 to 2.7, decreasing unnecessary procedures by 88%.

Conclusions:

• The Pigmented Lesion Assay (PLA) is a valuable tool for ruling out melanoma, reducing the need for surgical biopsies.
• PLA enhances diagnostic accuracy, minimizes invasive procedures, and offers significant healthcare cost savings.
• Integrating PLA into clinical practice improves patient care pathways for pigmented skin lesions.